News

The transaction adds the Universal Donor Cell technology to Astellas Pharma with which it will create cell therapy products that do not require Human Leukocyte Antigen (HLA) matching,

The FDA approval secured by the Johnson & Johnson (J&J) subsidiary comes after last week’s results of the phase 3 SPARTAN trial in patients with NM-CRPC in which

The trial included a placebo arm and an active control arm (adalimumab) for comparison with placebo, and studied patients who had never received a biologic disease-modifying anti-rheumatic drug

The programs will leverage CureVac’s RNActive prophylactic vaccine technology to develop mRNA-based vaccines designed to prevent influenza and malaria infection. These vaccines, which are flexible in their applications,

The approval is for Glatopa 40mg/mL as a fully-substitutable, AP-rated generic version of Teva Pharmaceutical Industries’ three times-a-week Copaxone 40mg/mL therapy (glatiramer acetate injection). Glatopa was approved by

Discovered by Kyowa Hakko Kirin, Tivozanib is an oral, once-daily and vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI). In the European Union, Norway and Iceland, tivozanib

The Phase III trial is an open label study in which adult patients with CAH, currently treated with a single or combination of generic steroids (standard-of-care), are randomised

Under the terms of the agreement, Horizon has licensed to the Partner a novel cell line engineering technology as well as non-exclusive rights to Horizon's proprietary Helitron transposon

The approval from the US Food and Drug Administration (FDA) is for CF patients having two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator